Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Combining CSF and Serum Biomarkers to Differentiate Mechanisms of Disability Worsening in Multiple Sclerosis

  • Monreal, Enric|||0000-0003-3293-0125
  • Fernández Velasco, José Ignacio|||0000-0001-9148-671X
  • Sainz De La Maza, Susana
  • Espiño, Mercedes
  • Villarrubia, Noelia
  • Roldán, Ernesto
  • Aladro, Yolanda|||0000-0001-9459-5452
  • Cuello, Juan Pablo
  • Ayuso-Peralta, Lucía
  • Rodero-Romero, Alexander
  • Chico-García, Juan Luís
  • Rodríguez-Jorge, Fernando
  • Quiroga-Varela, Ana
  • Rodríguez-Martín, Eulalia
  • Pilo, Belén
  • Martín Ávila, Guillermo
  • Martínez Ginés, María Luisa
  • García Domínguez, José Manuel
  • Rubio, Lluïsa
  • Llufriu, Sara|||0000-0003-4273-9121
  • Comabella López, Manuel|||0000-0002-2373-6657
  • Montalban, Xavier|||0000-0002-0098-9918
  • Álvarez Bravo, Gary|||0000-0003-0342-0177
  • Veiga-Gonzalez, José Luis
  • Masjuan, Jaime|||0000-0003-1329-0943
  • Costa-Frossard, Lucienne|||0000-0002-6512-4413
  • Villar, Luisa M.|||0000-0002-9067-3668
The combined use of serum and CSF biomarkers for prognostic stratification in multiple sclerosis (MS) remains underexplored. This multicenter observational study investigated associations between serum neurofilament light chain (sNfL), glial fibrillary acidic protein (sGFAP), and CSF lipid-specific IgM oligoclonal bands (LS-OCMB) with different forms of disability worsening, such as relapse-associated worsening (RAW), active progression independent of relapse activity (aPIRA), and non-active PIRA (naPIRA). A total of 535 patients with MS were included, all sampled within one year of disease onset. Biomarkers were quantified using single-molecule array and immunoblotting techniques, and CSF cell subsets were analyzed by flow cytometry. High sNfL z-scores and LS-OCMB positivity were independently associated with increased risk of RAW and aPIRA, collectively termed inflammatory-associated worsening (IAW), while elevated sGFAP levels predicted naPIRA. Patients with both high sNfL and LS-OCMB positivity had the highest risk of IAW. Among LS-OCMB-positive patients, higher regulatory T cell percentages were associated with lower sNfL levels, suggesting a protective role. Conversely, in LS-OCMB-negative patients, sNfL levels correlated with CSF C3 concentrations. These findings support the complementary role of sNfL, sGFAP, and LS-OCMB in identifying distinct mechanisms of disease worsening and may inform early personalized management strategies in MS.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Aging and neuroinflammation: Changes in immune cell responses, axon integrity, and motor function in a viral model of progressive multiple sclerosis

  • Mestre, Leyre
  • Alonso, Graciela
  • Feliú, Ana
  • Mecha, Miriam
  • Martín, C.
  • Villar, Luisa M.
  • Guaza, Carmen
Although aggravated multiple sclerosis (MS) disability has been reported in aged patients, the aging impact on immune cells remodeling within the CNS is not well understood. Here, we investigated the influence of aging on immune cells and the neuroinflammatory and neurodegenerative processes that occur in a well-established viral model of progressive MS. We found an anomalous presence of CD4 T, CD8T, B cells, and cells of myeloid lineage in the CNS of old sham mice whereas a blunted cellular innate and adaptive immune response was observed in Theiler's murine encephalomyelitis virus (TMEV) infected old mice. Microglia and macrophages show opposite CNS viral responses regarding cell counts in the old mice. Furthermore, enhanced expression of Programmed Death-ligand 1 (PD-L1) was found in microglia isolated from old TMEV-infected mice and not in isolated CNS macrophages. Immunocytochemical staining of microglial cells confirms the above differences between young and old mice. Age-related axonal loss integrity in the mouse spinal cord was found in TMEV mice, but a less marked neurodegenerative process was present in old sham mice compared with young sham mice. TMEV and sham old mice also display alterations in innate and adaptive immunity in the spleen compared to the young mice. Our study supports the need of new or adapted pharmacological strategies for MS elderly patients., Red Española de Esclerosis Múltiple, Grant/Award Number: RD 16/0015/0001 and RD16/0015/0021; MINECO, Grant/Award Number: SAF2016- 76449- R; Esclerosis Múltiple España, Grant/Award Number: EMMP2017
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple Sclerosis

  • Picón, C.
  • Tejeda-Velarde, A.
  • Fernández-Velasco, J.I.
  • Comabella, Manuel
  • Alvarez-Lafuente, R.
  • Quintana, E.
  • Sainz de la Maza, S.
  • Monreal, E.
  • Villarrubia, N.
  • Álvarez-Cermeño, José Carlos
  • Dominguez-Mozo, M.I.
  • Ramió-Torrentà, Lluís
  • Rodríguez-Martín, Eulalia
  • Roldán, E.
  • Aladro, Yolanda
  • Medina, S.
  • Espiño, Mercedes
  • Masjuán, J.
  • Matute-Blanch, Clara
  • Muñoz-San Martín, M.
  • Espejo, C.
  • Guaza, Carmen
  • Muriel, Alfonso
  • Costa-Frossard, L.
  • Villar, L.M.
Patients with multiple sclerosis (MS) suffer with age an early immunosenescence process, which influence the treatment response and increase the risk of infections. We explored whether lipid-specific oligoclonal IgM bands (LS-OCMB) associated with highly inflammatory MS modify the immunological profile induced by age in MS. This cross-sectional study included 263 MS patients who were classified according to the presence (M+, n=72) and absence (M-, n=191) of LS-OCMB. CSF cellular subsets and molecules implicated in immunosenescence were explored. In M- patients, aging induced remarkable decreases in absolute CSF counts of CD4+ and CD8+ T lymphocytes, including Th1 and Th17 cells, and of B cells, including those secreting TNF-alpha. It also increased serum anti-CMV IgG antibody titers (indicative of immunosenescence) and CSF CHI3L1 levels (related to astrocyte activation). In contrast, M+ patients showed an age-associated increase of TIM-3 (a biomarker of T cell exhaustion) and increased values of CHI3L1, independently of age. Finally, in both groups, age induced an increase in CSF levels of PD-L1 (an inductor of T cell tolerance) and activin A (part of the senescence-associated secretome and related to inflammaging). These changes were independent of the disease duration. Finally, this resulted in augmented disability. In summary, all MS patients experience with age a modest induction of T-cell tolerance and an activation of the innate immunity, resulting in increased disability. Additionally, M- patients show clear decreases in CSF lymphocyte numbers, which could increase the risk of infections. Thus, age and immunological status are important for tailoring effective therapies in MS., This work was supported by grants FIS-PI15/00513, FIS-PI18/00572 and RD16/0015/0001 from the Instituto de Salud Carlos III. Ministerio de Ciencia e Innovación, Spain and FEDER: "Una manera de hacer Europa".
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course

  • Gil Varea, Elia|||0000-0001-5144-4144
  • Urcelay, Elena|||0000-0001-8470-8396
  • Vilariño-Güell, Carles|||0000-0002-5612-5940
  • Costa, Carme|||0000-0001-9577-3839
  • Midaglia, Luciana|||0000-0001-7981-2228
  • Matesanz, Fuencisla|||0000-0002-9429-1819
  • Rodríguez Antigüedad, Alfredo|||0000-0001-5975-725X
  • Oksenberg, Jorge
  • Espino-Paisan, Laura
  • Dessa Sadovnick, A.
  • Saiz, Albert|||0000-0002-5793-8791
  • Villar, Luisa M.|||0000-0002-9067-3668
  • García Merino, Juan Antonio
  • Ramió-Torrentà, Lluís|||0000-0002-6999-1004
  • Triviño, Juan Carlos
  • Quintana, Ester|||0000-0001-8885-1931
  • Robles, René
  • Sánchez López, Antonio José|||0000-0001-7168-6175
  • Arroyo, Rafael
  • Alvarez-Cermeño, José C.|||0000-0002-1345-2837
  • Vidal-Jordana, Angela|||0000-0002-7270-5507
  • Malhotra, Sunny|||0000-0003-1112-7739
  • Fissolo, Nicolás|||0000-0002-7701-9346
  • Montalban, Xavier|||0000-0002-0098-9918
  • Comabella López, Manuel|||0000-0002-2373-6657
It remains unclear whether disease course in multiple sclerosis (MS) is influenced by genetic polymorphisms. Here, we aimed to identify genetic variants associated with benign and aggressive disease courses in MS patients. MS patients were classified into benign and aggressive phenotypes according to clinical criteria. We performed exome sequencing in a discovery cohort, which included 20 MS patients, 10 with benign and 10 with aggressive disease course, and genotyping in 2 independent validation cohorts. The first validation cohort encompassed 194 MS patients, 107 with benign and 87 with aggressive phenotypes. The second validation cohort comprised 257 patients, of whom 224 patients had benign phenotypes and 33 aggressive disease courses. Brain immunohistochemistries were performed using disease course associated genes antibodies. By means of single-nucleotide polymorphism (SNP) detection and comparison of allele frequencies between patients with benign and aggressive phenotypes, a total of 16 SNPs were selected for validation from the exome sequencing data in the discovery cohort. Meta-analysis of genotyping results in two validation cohorts revealed two polymorphisms, rs28469012 and rs10894768, significantly associated with disease course. SNP rs28469012 is located in CPXM2 (carboxypeptidase X, M14 family, member 2) and was associated with aggressive disease course (uncorrected p value < 0.05). SNP rs10894768, which is positioned in IGSF9B (immunoglobulin superfamily member 9B) was associated with benign phenotype (uncorrected p value < 0.05). In addition, a trend for association with benign phenotype was observed for a third SNP, rs10423927, in NLRP9 (NLR family pyrin domain containing 9). Brain immunohistochemistries in chronic active lesions from MS patients revealed expression of IGSF9B in astrocytes and macrophages/microglial cells, and expression of CPXM2 and NLRP9 restricted to brain macrophages/microglia. Genetic variants located in CPXM2, IGSF9B, and NLRP9 have the potential to modulate disease course in MS patients and may be used as disease activity biomarkers to identify patients with divergent disease courses. Altogether, the reported results from this study support the influence of genetic factors in MS disease course and may help to better understand the complex molecular mechanisms underlying disease pathogenesis. The online version of this article (10.1186/s12974-018-1307-1) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Gut dysbiosis and neuroimmune responses to brain infection with Theiler's murine encephalomyelitis virus

  • Carrillo-Salinas, Francisco J.|||0000-0002-7936-5859
  • Mestre, Leyre|||0000-0001-6970-2316
  • Mecha, Miriam
  • Feliú, Ana|||0000-0002-1157-1525
  • del Campo, Rosa|||0000-0003-1147-7923
  • Villarrubia, Noelia
  • Espejo, Carmen|||0000-0001-9949-5901
  • Montalban, Xavier|||0000-0002-0098-9918
  • Alvarez-Cermeño, José C.|||0000-0002-1345-2837
  • Villar, L. M.
  • Guaza, Carmen|||0000-0003-3240-9807
Recent studies have begun to point out the contribution of microbiota to multiple sclerosis (MS) pathogenesis. Theiler's murine encephalomyelitis virus induced demyelinating disease (TMEV-IDD) is a model of progressive MS. Here, we first analyze the effect of intracerebral infection with TMEV on commensal microbiota and secondly, whether the early microbiota depletion influences the immune responses to TMEV on the acute phase (14 dpi) and its impact on the chronic phase (85 dpi). The intracranial inoculation of TMEV was associated with a moderate dysbiosis. The oral administration of antibiotics (ABX) of broad spectrum modified neuroimmune responses to TMEV dampening brain CD4 + and CD8 + T infiltration during the acute phase. The expression of cytokines, chemokines and VP2 capsid protein was enhanced and accompanied by clusters of activated microglia disseminated throughout the brain. Furthermore, ABX treated mice displayed lower levels of CD4 + and CD8 + T cells in cervical and mesenteric lymph nodes. Increased mortality to TMEV was observed after ABX cessation at day 28pi. On the chronic phase, mice that survived after ABX withdrawal and recovered microbiota diversity showed subtle changes in brain cell infiltrates, microglia and gene expression of cytokines. Accordingly, the surviving mice of the group ABX-TMEV displayed similar disease severity than TMEV mice.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab

  • Walo-Delgado, Paulette Esperanza
  • Monreal, Enric|||0000-0003-3293-0125
  • Medina, Silvia|||0000-0002-6051-173X
  • Quintana, Ester|||0000-0001-8885-1931
  • Sainz de la Maza, Susana|||0000-0001-8605-0049
  • Fernández Velasco, José Ignacio|||0000-0001-9148-671X
  • Lapuente, Paloma
  • Comabella López, Manuel|||0000-0002-2373-6657
  • Ramió-Torrentà, Lluís|||0000-0002-6999-1004
  • Montalban, Xavier|||0000-0002-0098-9918
  • Midaglia, Luciana|||0000-0001-7981-2228
  • Villarrubia, Noelia
  • Carrasco-Sayalero, Angela
  • Rodríguez-Martín, Eulalia
  • Roldán, Ernesto
  • Meca-Lallana, Jose Eustasio|||0000-0001-5050-9890
  • Alvarez-Lafuente, Roberto|||0000-0002-3132-1486
  • Masjuan, Jaime|||0000-0003-1329-0943
  • Costa-Frossard, Lucienne|||0000-0002-6512-4413
  • Villar, Luisa M|||0000-0002-9067-3668
UDHEBRON, To explore if baseline blood lymphocyte profile could identify relapsing remitting multiple sclerosis (RRMS) patients at higher risk of developing secondary autoimmune adverse events (AIAEs) after alemtuzumab treatment. Multicenter prospective study including 57 RRMS patients treated with alemtuzumab followed for 3.25 [3.5-4.21] years, (median [interquartile range]). Blood samples were collected at baseline, and leukocyte subsets determined by flow cytometry. We had additional samples one year after the first cycle of alemtuzumab treatment in 39 cases. Twenty-two patients (38.6%) developed AIAEs during follow-up. They had higher B-cell percentages at baseline (p=0.0014), being differences mainly due to plasmablasts/plasma cells (PB/PC, p=0.0011). Those with no AIAEs had higher percentages of CD4+ T cells (p=0.013), mainly due to terminally differentiated (TD) (p=0.034) and effector memory (EM) (p=0.031) phenotypes. AIAEs- patients also showed higher values of TNF-alpha-producing CD8+ T cells (p=0.029). The percentage of PB/PC was the best variable to differentiate both groups of patients. Baseline values >0.10% closely associated with higher AIAE risk (Odds ratio [OR]: 5.91, 95% CI: 1.83-19.10, p=0.004). When excluding the 12 patients with natalizumab, which decreases blood PB/PC percentages, being the last treatment before alemtuzumab, baseline PB/PC >0.1% even predicted more accurately the risk of AIAEs (OR: 11.67, 95% CI: 2.62-51.89, p=0.0007). The AIAEs+ group continued having high percentages of PB/PC after a year of alemtuzumab treatment (p=0.0058). A PB/PC percentage <0.1% at baseline identifies MS patients at low risk of secondary autoimmunity during alemtuzumab treatment.​